Cargando…

Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin

BACKGROUND: To study the pathogenesis of diabetic cardiomyopathy, reliable animal models of type 2 diabetes are required. Physiologically relevant rodent models are needed, which not only replicate the human pathology but also mimic the disease process. Here we characterised cardiac metabolic abnorm...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansor, Latt S, Gonzalez, Eileen R, Cole, Mark A, Tyler, Damian J, Beeson, Jessica H, Clarke, Kieran, Carr, Carolyn A, Heather, Lisa C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849358/
https://www.ncbi.nlm.nih.gov/pubmed/24063408
http://dx.doi.org/10.1186/1475-2840-12-136
_version_ 1782293912088477696
author Mansor, Latt S
Gonzalez, Eileen R
Cole, Mark A
Tyler, Damian J
Beeson, Jessica H
Clarke, Kieran
Carr, Carolyn A
Heather, Lisa C
author_facet Mansor, Latt S
Gonzalez, Eileen R
Cole, Mark A
Tyler, Damian J
Beeson, Jessica H
Clarke, Kieran
Carr, Carolyn A
Heather, Lisa C
author_sort Mansor, Latt S
collection PubMed
description BACKGROUND: To study the pathogenesis of diabetic cardiomyopathy, reliable animal models of type 2 diabetes are required. Physiologically relevant rodent models are needed, which not only replicate the human pathology but also mimic the disease process. Here we characterised cardiac metabolic abnormalities, and investigated the optimal experimental approach for inducing disease, in a new model of type 2 diabetes. METHODS AND RESULTS: Male Wistar rats were fed a high-fat diet for three weeks, with a single intraperitoneal injection of low dose streptozotocin (STZ) after fourteen days at 15, 20, 25 or 30 mg/kg body weight. Compared with chow-fed or high-fat diet fed control rats, a high-fat diet in combination with doses of 15–25 mg/kg STZ did not change insulin concentrations and rats maintained body weight. In contrast, 30 mg/kg STZ induced hypoinsulinaemia, hyperketonaemia and weight loss. There was a dose-dependent increase in blood glucose and plasma lipids with increasing concentrations of STZ. Cardiac and hepatic triglycerides were increased by all doses of STZ, in contrast, cardiac glycogen concentrations increased in a dose-dependent manner with increasing STZ concentrations. Cardiac glucose transporter 4 protein levels were decreased, whereas fatty acid metabolism-regulated proteins, including uncoupling protein 3 and pyruvate dehydrogenase (PDH) kinase 4, were increased with increasing doses of STZ. Cardiac PDH activity displayed a dose-dependent relationship between enzyme activity and STZ concentration. Cardiac insulin-stimulated glycolytic rates were decreased by 17% in 15 mg/kg STZ high-fat fed diabetic rats compared with control rats, with no effect on cardiac contractile function. CONCLUSIONS: High-fat feeding in combination with a low dose of STZ induced cardiac metabolic changes that mirror the decrease in glucose metabolism and increase in fat metabolism in diabetic patients. While low doses of 15–25 mg/kg STZ induced a type 2 diabetic phenotype, higher doses more closely recapitulated type 1 diabetes, demonstrating that the severity of diabetes can be modified according to the requirements of the study.
format Online
Article
Text
id pubmed-3849358
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38493582013-12-05 Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin Mansor, Latt S Gonzalez, Eileen R Cole, Mark A Tyler, Damian J Beeson, Jessica H Clarke, Kieran Carr, Carolyn A Heather, Lisa C Cardiovasc Diabetol Original Investigation BACKGROUND: To study the pathogenesis of diabetic cardiomyopathy, reliable animal models of type 2 diabetes are required. Physiologically relevant rodent models are needed, which not only replicate the human pathology but also mimic the disease process. Here we characterised cardiac metabolic abnormalities, and investigated the optimal experimental approach for inducing disease, in a new model of type 2 diabetes. METHODS AND RESULTS: Male Wistar rats were fed a high-fat diet for three weeks, with a single intraperitoneal injection of low dose streptozotocin (STZ) after fourteen days at 15, 20, 25 or 30 mg/kg body weight. Compared with chow-fed or high-fat diet fed control rats, a high-fat diet in combination with doses of 15–25 mg/kg STZ did not change insulin concentrations and rats maintained body weight. In contrast, 30 mg/kg STZ induced hypoinsulinaemia, hyperketonaemia and weight loss. There was a dose-dependent increase in blood glucose and plasma lipids with increasing concentrations of STZ. Cardiac and hepatic triglycerides were increased by all doses of STZ, in contrast, cardiac glycogen concentrations increased in a dose-dependent manner with increasing STZ concentrations. Cardiac glucose transporter 4 protein levels were decreased, whereas fatty acid metabolism-regulated proteins, including uncoupling protein 3 and pyruvate dehydrogenase (PDH) kinase 4, were increased with increasing doses of STZ. Cardiac PDH activity displayed a dose-dependent relationship between enzyme activity and STZ concentration. Cardiac insulin-stimulated glycolytic rates were decreased by 17% in 15 mg/kg STZ high-fat fed diabetic rats compared with control rats, with no effect on cardiac contractile function. CONCLUSIONS: High-fat feeding in combination with a low dose of STZ induced cardiac metabolic changes that mirror the decrease in glucose metabolism and increase in fat metabolism in diabetic patients. While low doses of 15–25 mg/kg STZ induced a type 2 diabetic phenotype, higher doses more closely recapitulated type 1 diabetes, demonstrating that the severity of diabetes can be modified according to the requirements of the study. BioMed Central 2013-09-24 /pmc/articles/PMC3849358/ /pubmed/24063408 http://dx.doi.org/10.1186/1475-2840-12-136 Text en Copyright © 2013 Mansor et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Mansor, Latt S
Gonzalez, Eileen R
Cole, Mark A
Tyler, Damian J
Beeson, Jessica H
Clarke, Kieran
Carr, Carolyn A
Heather, Lisa C
Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin
title Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin
title_full Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin
title_fullStr Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin
title_full_unstemmed Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin
title_short Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin
title_sort cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849358/
https://www.ncbi.nlm.nih.gov/pubmed/24063408
http://dx.doi.org/10.1186/1475-2840-12-136
work_keys_str_mv AT mansorlatts cardiacmetabolisminanewratmodeloftype2diabetesusinghighfatdietwithlowdosestreptozotocin
AT gonzalezeileenr cardiacmetabolisminanewratmodeloftype2diabetesusinghighfatdietwithlowdosestreptozotocin
AT colemarka cardiacmetabolisminanewratmodeloftype2diabetesusinghighfatdietwithlowdosestreptozotocin
AT tylerdamianj cardiacmetabolisminanewratmodeloftype2diabetesusinghighfatdietwithlowdosestreptozotocin
AT beesonjessicah cardiacmetabolisminanewratmodeloftype2diabetesusinghighfatdietwithlowdosestreptozotocin
AT clarkekieran cardiacmetabolisminanewratmodeloftype2diabetesusinghighfatdietwithlowdosestreptozotocin
AT carrcarolyna cardiacmetabolisminanewratmodeloftype2diabetesusinghighfatdietwithlowdosestreptozotocin
AT heatherlisac cardiacmetabolisminanewratmodeloftype2diabetesusinghighfatdietwithlowdosestreptozotocin